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Abstract
Background—Higher breast cancer mortality rates for African-American than non-Hispanic 
white women are well documented; however, it remains uncertain if this disparity occurs in 
disease subgroups defined by tumor molecular markers and stage at diagnosis. We examined 
racial differences in outcome according to subtype and stage in a diverse, population-based series 
of 103,498 patients.
Methods—We obtained data for all invasive breast cancers diagnosed 1/1/2005-12/31/2012 and 
followed through 12/31/2012 among 93,760 non-Hispanic white and 9,738 African-American 
women in California. Molecular subtypes were categorized according to tumor expression of 
hormone receptor (HR, based on estrogen and progesterone receptors) and human epidermal 
growth factor receptor 2 (HER2). Cox proportional hazards models were used to calculate hazard 
ratios (HR) and 95% confidence intervals (CI) for breast cancer-specific mortality.
Results—After adjustment for patient, tumor and treatment characteristics, outcomes were 
comparable by race for Stage I or IV cancer regardless of subtype, and HR+/HER2+ or HR-/
HER2+ cancer regardless of stage. We found substantially higher hazards of breast cancer death 
among African-American women with Stage II/III HR+/HER2- (HR, 1.31, 95% CI, 1.03-1.65, and 
HR, 1.39, 95% CI, 1.10-1.75, respectively) and Stage III triple-negative cancers relative to whites.
Conclusions—There are substantial racial/ethnic disparities among patients with Stages II/III 
HR+/HER2- and Stage III triple-negative breast cancers but not for other subtype and stage.
Impact—These data provide insights to assess barriers to targeted treatment (e.g. trastuzumab or 
endocrine therapy) of particular subtypes of breast cancer among African-American patients.
Keywords
Disparity; breast cancer; subtype; stage; mortality
Corresponding Author: Christina A. Clarke, PhD, MPH, Research Scientist, Cancer Prevention Institute of California, 2201 Walnut 
Avenue, Suite 300, Fremont, CA 94538-2334, tina@cpic.org. 
Conflict of Interest: The authors declare that there is no conflict of interest.
HHS Public Access
Author manuscript
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2016 July 01.
Published in final edited form as:














Although breast cancer mortality rates have declined in the United States over the past few 
decades (1), African-American women experience substantially higher breast cancer 
mortality than non-Hispanic white (white) women (2, 3). The mortality disparity is 
especially noteworthy in light of the lower incidence rate of breast cancer among African-
American than white women (4, 5) .
This racial/ethnic disparity in breast cancer outcomes has been well studied and prior studies 
have set forth biological and non-biological explanations for the mortality difference (6-9). 
African-American women are more likely to be diagnosed at a later stage of breast cancer 
than whites, which may be due to factors such as limited primary care (10) or longer follow-
up time after an abnormal or inconclusive screening mammogram (11, 12). Poorer survival 
also may be influenced by patient social context disproportionately affecting African-
American women, specifically socioeconomic deprivation at the individual or neighborhood 
levels, and social injustice (13, 14). However, there is also evidence that, relative to white 
women, breast cancer among African-American women may be biologically more 
aggressive and more likely to express molecular markers [i.e. estrogen receptor (ER) and 
progesterone receptor (PR) (together referred to as hormone receptor (HR)), and human 
epidermal growth factor receptor 2 (HER2)] associated with worse outcomes (7, 15-17). In 
particular, African-American women are more likely than white women to be diagnosed 
with triple-negative breast cancer, which, because of its lack of expression for the three 
molecular markers, does not currently have targeted treatment options (7, 15-17). A few 
studies have measured the contribution of molecular subtype to racial/ethnic disparities in 
breast cancer survival (18-20), but the findings were inconsistent when comparing survival 
in African-American patients with whites. One study found mortality risk difference 
between African-American and white women occurs only among older women diagnosed 
with luminal A/p53- but not with triple-negative breast cancer (18), whereas another two 
studies suggested higher overall mortality (19) and breast cancer specific mortality (20) in 
African-American than white patients with the triple-negative subtype. To date, there have 
been no datasets large enough to examine racial/ethnic mortality disparities by tumor 
molecular subtypes and stage at diagnosis, the two important prognostic determinants of 
survival, to further isolate the subgroups with the worst disparities.
We took advantage of the California Cancer Registry, for which breast cancers defined by 
ER, PR and HER2 status are reported for a particularly large and racially/ethnically diverse 
population to study overall and breast-cancer specific mortality among white and African-
American women diagnosed with invasive breast cancer during the period 2005-2012. We 
assessed whether mortality differences persisted across molecular subtype and stage at 
diagnosis, defined jointly. We also assessed the contributions of clinical and demographic 
characteristics, including first course of treatment, neighborhood socioeconomic status 
(SES), and health insurance status, to racial/ethnic mortality differences.
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We obtained from the California Cancer Registry (CCR) information about all 104,051 
white or African-American female California residents diagnosed with a first primary, 
invasive breast cancer [International Classification of Disease for Oncology, 3rd Edition, 
(ICD-O-3) site codes C50.0-50.9, with the following histological subtypes of breast 
carcinoma or adenocarcinoma: 8000, 8010, 8020, 8022, 8050, 8140, 8201-8230, 8255, 8260, 
8401, 8453, 8480-8530, and 8575] between 1/1/2005 and 12/31/2012. We excluded patients 
who were diagnosed by mammography/xerography (n = 51) or death certificate/autopsy 
only (n=502). The final study population included 103,498 patients, of whom 93,760 were 
white and 9,738 were African-American. For each patient, we obtained information 
routinely abstracted from the medical record on age at diagnosis, race/ethnicity (white and 
African-American), census-block group of residence, AJCC stage at diagnosis [I, II, III, IV, 
or unstaged /not applicable (NA)], tumor size [in centimeters (cm), microinvasion, diffuse, 
or unknown], grade (low, high, or unknown), primary source of payment at the time of 
initial diagnosis and/or treatment (public insurance, private insurance, no insurance/self-pay, 
and insurance status unknown), ER, PR and HER2 tumor expression status, as well as 
treatment modalities [surgery, radiation, chemotherapy (endocrine therapy, although 
available, is under-captured in cancer registry data)] received within the first 12 months after 
diagnosis. We also obtained vital status as of 12/31/2012 (maximum follow-up of 7 years) 
and the underlying cause of death for the deceased. This project was overseen by the 
Institutional Review Board of the Cancer Prevention Institute of California.
In addition, because individual patient-level SES information is not collected by the CCR, 
we developed a multi-component measure of neighborhood SES based on patients' 
residential census block group at diagnosis, incorporating 2000 U.S. Census (for cases 
diagnosed in 2005) and 2006-2010 American Community Survey data (for cases diagnosed 
2006+) on education, occupation, unemployment, household income, poverty, rent, and 
house values (21, 22). Patient residential address at diagnosis was geocoded to a census 
block group. In our study, 1.6% of all cases could not be geocoded due to incomplete 
address. Each patient was assigned a neighborhood SES quintile, based on the distribution of 
SES across census block groups in California.
Breast cancer subtype definition
The CCR has collected information on the expression of ER and PR since 1990 and of 
HER2 since 1999 (23). Before 2005, 41% of cases lacked HER2 data, but data completeness 
has increased to at least 83% since that time. Because of the reduced reliability of HER2 
receptor status (17) and data completeness prior to 2005, we limited our analyses to between 
2005 and 2011, the most recent years for which more complete data were available. Each 
marker was reported as positive, negative, borderline, not tested/ recorded, or unknown, 
based on the medical record information recorded by the reporting facility. We classified the 
breast cancers into four mutually exclusive subtype categories: HR+/HER2- was defined as 
ER or PR positive and HER2 negative; HR+/HER2+ as ER or PR positive and HER2 
positive; HR-/HER2+ as ER and PR negative and HER2 positive; and triple-negative as ER, 
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PR, and HER2 negative (7, 17, 23-25). Of the 103,498 cancers, 14,287 (13.8%) did not have 
information needed to assign to one of these subtypes, including 8,597 cancers (8.3%) for 
whom only HER2 status was unknown, 608 cancers (0.6%) for whom only HR status was 
unknown, and 5,690 cancers (5.5%) for whom both HR and HER2 status were unknown. 
Cancers for which subtype was missing did not differ statistically significantly with respect 
to patient race/ethnicity from those for which subtype was known.
Statistical Analysis
The Mantel-Haenszel chi-square test was used to compute P-values for differences in 
distribution of patient and clinical characteristics between white and African-American 
patients. Cox proportional hazards regression was used to estimate hazard ratios (HR) and 
corresponding associated 95% confidence intervals (CI) with independent variables added in 
turn to understand their individual effects. The Kaplan-Meier method and the log-rank test 
were used to show and test differences in overall survival for patients diagnosed at each 
stage by breast cancer subtype.
For deceased patients, survival time was measured in days from the date of diagnosis to the 
date of death from breast cancer. Patients who died from other causes were censored at the 
time of death. Patients alive at the study end date (12/312012) were censored at this time or 
at the date of last follow-up (i.e., last known contact). The proportional hazards assumption 
was examined by statistical testing of the correlation between weighted Schoenfeld residuals 
and logarithmically transformed survival time. No violations of the assumption were 
observed. Given that proportional hazards varied by stage at diagnosis (AJCC Stage I-IV 
and unknown), it was included as a stratifying variable in all Cox regression models, 
allowing the baseline hazard to vary by stage. All models were adjusted for clustering by 
block group. Ninety-eight percent of censored patients had a follow-up date within 2 years 
of the study end date; the proportion of patients without recent follow-up information did 
not differ by race/ethnicity nor by neighborhood SES.
Cells with fewer than five cases are not shown for privacy purposes. All statistical tests were 
carried out using SAS software version 9.3 (SAS Institute, Cary, North Carolina). All P-
values reported were two-sided, and those that were <0.05 were considered to be statistically 
significant.
Results
In this population-based cohort of 93,760 white and 9,738 African-American breast cancer 
patients, the mean (± standard deviation) age at diagnosis was higher for white (62.3 ±13.6 
years) than African-American women (58.8 ±13.7 years). Compared to whites, African-
American patients were more likely to be diagnosed at a younger age, to be unmarried, to 
live in lower SES neighborhoods, to be diagnosed at a more advanced stage, to have larger 
tumors, and to have public insurance or no insurance (all Ps < 0.05, Table 1). Approximately 
20% of African-American, while only 10% white patients were diagnosed with triple-
negative breast cancer.
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After a mean follow-up time of 3.5 (±2.3) years, African-American patients had an 18% 
overall increased risk of death from breast cancer (HR, 1.18, 95% CI, 1.10-1.27) compared 
to white patients after including stage as a stratifying variable and adjusting for molecular 
subtype, age at diagnosis, marital status, tumor characteristics, treatment modalities, 
neighborhood SES, and insurance status (data not shown on table). This deficit in breast 
cancer specific survival was observed across all molecular subtypes (all P log-rank < 0.01, 
Figure 1). After adjusting for tumor characteristics and first course of treatment, African-
American women with HR+/HER2- and triple-negative breast cancer had a significantly 
higher hazard of breast cancer death compared with whites (HR, 1.29, 95% CI, 1.14-1.45 for 
HR+/HER2- and HR, 1.22, 95% CI, 1.08-1.39 for triple-negative breast cancer, models 1 
and 2, Table 2). After further adjustment with neighborhood SES and insurance status 
(models 3 and 4, Table 2), African-American women with HR+/HER2- and triple-negative 
breast cancer consistently showed elevated hazard of breast cancer-specific death (HR, 1.27, 
95% CI, 1.12-1.43 and HR, 1.21, 95% CI, 1.06-1.37, respectively), compared with white 
patients.
When analyses were stratified by stage at diagnosis, we found worse breast cancer survival 
in African-American women diagnosed within Stage II-IV for HR+/HER2- and triple-
negative breast cancers, and Stage III for HR-/HER2+ breast cancers (all P log-rank < 0.05), 
but not in any other subgroups defined jointly by molecular subtype and stage (all Plog-rank 
>0.05, figures not shown). There were no differences in breast cancer specific mortality 
between African-American and white patients within HR-/HER2+ breast cancer regardless 
of stage, and Stage I and IV breast cancer regardless of molecular subtype, even after 
adjustment for all prognostic factors, including age, marital status, tumor characteristics, 
treatment, neighborhood SES and insurance status (stage stratified model 4, Table 2). 
However, higher mortality remained for African-Americans compared with whites for some 
molecular subtype/stage subgroups. Among Stages II and III HR+/HER2- patients, African-
American women experienced significantly increased risk of breast cancer specific death 
[HR (95%CI) 1.31 (1.03-1.65) and 1.39 (1.10-1.75), for Stage II and III patients, 
respectively], comparing to white women. Also, in patients diagnosed with Stage III triple-
negative breast cancer, African-American women had a 37% (95% CI, 1.05-1.55) higher 
hazard of breast cancer death relative to whites.
Discussion
In this large, representative series of women diagnosed with invasive breast cancer in 
California in recent years, we found that disparities in breast cancer mortality between 
African-Americans and whites varied according to molecular subtype and stage of the 
tumor. Within Stages II and III HR+/HER2- breast cancer, we found 31-39% higher rate of 
breast cancer specific death in African-American than white patients after adjustment for 
demographic factors, tumor characteristics, first course of treatment, neighborhood SES, and 
insurance status. However, these factors, especially neighborhood SES, fully explained 
overall mortality differences in Stage I HR+/HER2-, Stage I and II HR+/HER2+, and Stage 
II triple-negative breast cancer (data not shown), suggesting critical roles for early detection 
and early diagnosis in efforts to eliminate disparities. This finding is consistent with prior 
reports of a substantial impact of neighborhood SES on racial disparities in breast cancer 
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mortality (26-29). In this California cohort, a much higher proportion of African-American 
patients were diagnosed with triple-negative breast cancer, a more aggressive subtype (19, 
30), than whites. Our study sets forth Stages II and III HR+/HER2- and Stage III triple-
negative breast cancers as particularly important areas for research to identify additional 
biological tumor characteristics and non-biological factors that may contribute to the racial/
ethnic disparity. Prior studies focusing on triple-negative breast cancer reported that 
molecular factors, including hereditary gene expressions, alterations in p53 and genomic 
copy number, tumor DNA methylation status, and mutations in DNA repair genes (31-34), 
as well as epidemiological factors, including reproductive and patient demographic factors 
(35), differed in prevalence among racial groups. These data are not yet reported to cancer 
registries, and thus, the extent to which they may explain survival disparities is not yet fully 
understood.
Our primary finding of disparities occurring in certain breast cancer patient subgroups, 
which included the subtype with available targeted therapies (36) and the early stages 
curable by adequate treatment, is noteworthy. Specifically, study suggests that African-
Americans are primarily and persistently at higher risk of death only for HR+/HER2- breast 
cancers at Stages II and III, for which breast cancers respond favorably to anti-endocrine 
therapy or trastuzumab therapy (37). This underscores the central role of treatment in the 
black/white disparity in breast cancer, even though no race/ethnicity differences in adjuvant 
hormone therapy use were identified in two recent studies (38, 39). Unfortunately, 
information on endocrine therapies is under-captured in cancer registry data, and specific 
information regarding receipt of trastuzumab is not reported. Cancer registry first course of 
treatment data do not include information on specific components of chemotherapy, nor 
aspects such as timing, dosage, completion of regimen, guideline adherence, or details on 
the specific types of surgery, radiation, endocrine, or chemotherapy agents.
Other non-biological factors and factors independent of stage at presentation, such as 
residual treatment/healthcare differences due to social and health system factors, may also 
explain a significant portion of the mortality disparity. Racial/ethnic differences in receipt of 
treatment may exist even among those with insurance, and may be attributable to patient 
(e.g., comorbidities) factors, healthcare system factors, or differences in tumor biology or 
response to treatments. African-American women are less likely to receive adequately 
dosed, timely and appropriate administration of chemotherapy (40-43), and adjuvant 
radiation therapy after breast-conserving surgery (44, 45). Historically underserved 
populations, including African-Americans, generally benefit less from medical advances 
(46). It remains to be seen whether the shift towards more personalized treatment options 
based in gene expression testing/profiling, including evolving HER2-directed and anti-
endocrine therapies, will result in more pronounced mortality disparities for African-
Americans. Deficiencies in treatment and care among African-American breast cancer 
patients may result from a number of contributing causes. While health insurance status is 
the most referenced and an important barrier (47-49), a number of additional factors, such as 
out-of-pocket financial hardship caused by cancer care (50), need for time taken from work 
(51), and problems with travel (52, 53), may also disproportionally affect the cancer 
treatment and care of African-American women. In addition, the nuanced role of patient-
physician communication, which is understood to affect physicians' care recommendations 
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and patients' compliance with treatment (54), is also relevant, as African-American patients 
have been reported to have more misunderstandings about treatment (55, 56) and lower 
satisfaction or trust of the health care system (57). Thus, although overall, the quality of 
breast cancer care is improving and mortality rates is declining, disparities still remain, such 
that African-Americans may still receive insufficient, poorer-quality, and diminished access 
to care as compared to whites (10).
Our study has the strength of being population-based with large numbers of African-
American and white cases to enable examination of breast cancer mortality across 
combinations of subtypes and stage. While we did adjust outcomes according to available 
demographic and clinical characteristics, we lacked clinical information on detailed 
regimens for treatment and treatments received after the first course. Another limitation is 
our inability to control for individual-level measures of SES, like level of education or 
income. While neighborhood and individual SES are strongly correlated, neighborhood SES 
under-estimates associations observed with individual-level markers (58). Furthermore, our 
mean follow-up was 3.5 years (and our maximum 8 years), because of the recency of HER2 
data availability; thus, our results cannot speak to longer-term survival. However, it has been 
reported that the disparity in breast cancer mortality between African-Americans and NH 
whites is more pronounced during the first few years after diagnosis (59). Regardless, 
studies with longer follow-up are warranted.
In summary, we found an important mortality disparity between African-Americans and NH 
whites within the relatively curable subtypes of Stages II and III HR+/HER2- and Stage III 
triple-negative breast cancers after consideration of demographic, treatment, tumor 
characteristics, neighborhood SES, and insurance status. Our study suggests that healthcare 
delivery differences due to social and health system factors may contribute to the mortality 
disparity, given the importance of optimally targeted therapy to curing tumors of these 
stages and subtypes. Future research should assess biomedical, contextual and individual-
level factors leading to inadequate treatment of African-American women with Stages II and 
III HR+/HER2- cancers and Stage III triple-negative breast cancers.
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Breast cancer-specific survival for non-Hispanic White and African-American patients by 
breast cancer subtype, California 2005-2012. All Plog-rank < 0.01
The vertical axis represents survival probability; the horizontal axis represents survival time 
in days. A) HR+/HER2- ; B) HR+/HER2+; C) HR-/HER2+ ; D) Triple Negative.
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Table 1
Demographic and clinical characteristics for white and African-American women 
diagnosed with invasive breast cancer, California, 2005-2012
Non-Hispanic White
Total N (n=93,760) (%)
African-American
Total N (n=9,738) (%)
Patient demographic characteristics
Age at diagnosis
 <45 years 8680 (9.3%) 1448 (14.9%)
 45-49 years 9146 (9.8%) 1216 (12.5%)
 50-54 years 10935 (11.7%) 1333 (13.7%)
 55-59 years 12036 (12.8%) 1344 (13.8%)
 60-64 years 12787 (13.6%) 1212 (12.4%)
 65+ 40176 (42.8%) 3185 (32.7%)
Marital status at diagnosis
 Married 51828 (55.3%) 3313 (34.0%)
 Never married 12789 (13.6%) 3036 (31.2%)
 Previously married 25959 (27.7%) 2997 (30.8%)
 Unknown 3184 (3.4%) 392 (4.0%)
Neighborhood SES in quintile
 1, lowest 7054 (7.5%) 2543 (26.1%)
 2 13944 (14.9%) 2472 (25.4%)
 3 19294 (20.6%) 2066 (21.2%)
 4 24110 (25.7%) 1680 (17.3%)
 5, highest 29358 (31.3%) 977 (10.0%)
Tumor characteristics Subtype 1
 HR+/HER2- 59341 (63.3%) 4813 (49.4%)
 HR+/HER2+ 8474 (9.0%) 1050 (10.8%)
 HR-/HER2+ 3913 (4.2%) 527 (5.4%)
 Triple negative 8589 (9.2%) 1896 (19.5%)
 Unclassified 13443 (14.3%) 1452 (14.9%)
AJCC stage at diagnosis
 I 45503 (48.5%) 3542 (36.4%)
 II 29803 (31.8%) 3472 (35.7%)
 III 10330 (11.0%) 1500 (15.4%)
 IV 4291 (4.6%) 731 (7.5%)
 Unknown/unstaged 3833 (4.1%) 493 (5.1%)
Tumor Grade 2
 Low 61032 (65.1%) 4689 (48.2%)
 High 26374 (28.1%) 4325 (44.4%)
 Unknown 6354 (6.8%) 724 (7.4%)
Lymph node involvement
 Negative 61967 (66.1%) 5567 (57.2%)
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Non-Hispanic White
Total N (n=93,760) (%)
African-American
Total N (n=9,738) (%)
 Positive 29150 (31.1%) 3806 (39.1%)
 Unknown 2643 (2.8%) 365 (3.7%)
Size
 0-2.00 cm 54913 (58.6%) 4526 (46.5%)
 2.01-5.00 cm 27256 (29.1%) 3359 (34.5%)
 >5.00 cm 6393 (6.8%) 1117 (11.5%)
 Microinvasion 435 (0.5%) 94 (1.0%)
 Diffuse 886 (0.9%) 113 (1.2%)
 Unknown 3877 (4.1%) 529 (5.4%)
Insurance status 3
 Private 57025 (60.8%) 5435 (55.8%)
 Medicare 16827 (17.9%) 956 (9.8%)
 Military 672 (0.7%) 118 (1.2%)
 Public/Medicaid 15350 (16.4%) 2822 (29.0%)
 Uninsured/self-pay 624 (0.7%) 139 (1.4%)
 Unknown 3262 (3.5%) 268 (2.8%)
Surgery
 No 6711 (7.2%) 1114 (11.4%)
 Yes 86544 (92.3%) 8586 (88.2%)
 Unknown 505 (0.5%) 38 (0.4%)
Chemotherapy
 No 58310 (62.2%) 4923 (50.6%)
 Yes 33889 (36.1%) 4663 (47.9%)
 Unknown 1561 (1.7%) 152 (1.6%)
Radiation therapy
 No 48195 (51.4%) 5567 (57.2%)
 Yes 45463 (48.5%) 4165 (42.8%)
 Unknown 102 (0.1%) 6 (0.1%)
1
Human epidermal growth factor receptor 2 (HER2), hormone receptor (HR), triple-negative (estrogen-receptor negative, progesterone- receptor, 
and human epidermal growth factor receptor 2)
2
Low grade was defined as tumor grade I and II; high grade was defined as tumor grade IIII and IV.
3
Public insurance included Medicaid and other government-assisted programs; and private insurance included health maintenance organizations, 
preferred provider organizations, managed care not otherwise specified, and military care.
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